quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:12:59·898d
NEWSRelease
BioMarin Pharmaceutical Inc. logo
iShares Nasdaq Biotechnology Index Fund logo

Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change

BMRN· BioMarin Pharmaceutical Inc.IBB· iShares Nasdaq Biotechnology Index Fund
Health Care
Original source

Companies

  • BMRN
    BioMarin Pharmaceutical Inc.
    Health Care
  • IBB
    iShares Nasdaq Biotechnology Index Fund
    n/a

Recent analyst ratings

  • Jan 28BMRNUpdateBarclays$80.00
  • Jan 20BMRNUpdateCanaccord Genuity$98.00
  • Dec 3BMRNUpdateLeerink Partners$60.00
  • Nov 6BMRNUpdateStifel$61.00
  • Sep 8BMRNUpdateH.C. Wainwright$60.00
  • Sep 3BMRNUpdateRaymond James$85.00

Related

  • SEC11h
    SEC Form 8-K filed by BioMarin Pharmaceutical Inc.
  • PR2d
    BioMarin Announces Board Leadership Transition
  • SEC2d
    SEC Form DEFA14A filed by BioMarin Pharmaceutical Inc.
  • SEC2d
    SEC Form DEF 14A filed by BioMarin Pharmaceutical Inc.
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by BioMarin Pharmaceutical Inc.
  • INSIDER35d
    SEC Form 4 filed by Davis George Eric
  • INSIDER35d
    SEC Form 4 filed by Guyer Charles Greg
  • INSIDER35d
    SEC Form 4 filed by Mueller Brian
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022